User login
Key clinical point: The risk for the first and metachronous colorectal cancer (CRC) was considerably different in patients with Lynch syndrome (LS), Lynch-like syndrome (LLS), and familial colorectal cancer type X (FCCX), with the risk being highest in LS.
Major finding: Compared with LS, the cumulative CRC risk was significantly lower in FCCX without (hazard ratio [HR], 0.13; 95% confidence interval [CI], less than 0.01-0.95) and with (HR, 0.19; 95% CI, 0.02-0.69) previous CRC. In addition, CRC risk was significantly lower in the group of patients with LLS with a previous CRC than LS group (HR, 0.54; 95% CI, 0.30-0.92).
Study details: Findings are from a prospective analysis of 1,448 patients who were classified as having FCCX (n=103), LLS (n=481), or LS (n=864).
Disclosures: This study was supported by grants from the German Cancer Aid. D Vangala declared receiving speaker’s honoraria, travel support, and congress registration fees from various sources. All other authors declared no conflict of interests.
Source: Bucksch K et al. Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.
Key clinical point: The risk for the first and metachronous colorectal cancer (CRC) was considerably different in patients with Lynch syndrome (LS), Lynch-like syndrome (LLS), and familial colorectal cancer type X (FCCX), with the risk being highest in LS.
Major finding: Compared with LS, the cumulative CRC risk was significantly lower in FCCX without (hazard ratio [HR], 0.13; 95% confidence interval [CI], less than 0.01-0.95) and with (HR, 0.19; 95% CI, 0.02-0.69) previous CRC. In addition, CRC risk was significantly lower in the group of patients with LLS with a previous CRC than LS group (HR, 0.54; 95% CI, 0.30-0.92).
Study details: Findings are from a prospective analysis of 1,448 patients who were classified as having FCCX (n=103), LLS (n=481), or LS (n=864).
Disclosures: This study was supported by grants from the German Cancer Aid. D Vangala declared receiving speaker’s honoraria, travel support, and congress registration fees from various sources. All other authors declared no conflict of interests.
Source: Bucksch K et al. Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.
Key clinical point: The risk for the first and metachronous colorectal cancer (CRC) was considerably different in patients with Lynch syndrome (LS), Lynch-like syndrome (LLS), and familial colorectal cancer type X (FCCX), with the risk being highest in LS.
Major finding: Compared with LS, the cumulative CRC risk was significantly lower in FCCX without (hazard ratio [HR], 0.13; 95% confidence interval [CI], less than 0.01-0.95) and with (HR, 0.19; 95% CI, 0.02-0.69) previous CRC. In addition, CRC risk was significantly lower in the group of patients with LLS with a previous CRC than LS group (HR, 0.54; 95% CI, 0.30-0.92).
Study details: Findings are from a prospective analysis of 1,448 patients who were classified as having FCCX (n=103), LLS (n=481), or LS (n=864).
Disclosures: This study was supported by grants from the German Cancer Aid. D Vangala declared receiving speaker’s honoraria, travel support, and congress registration fees from various sources. All other authors declared no conflict of interests.
Source: Bucksch K et al. Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.